Which has higher valuation & earnings, BBIO or OGN?

Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 25.63 -$724.93M -$3.74 N/A Organon & Co. $6.22B 0.57 $187M $0.93 14.40

Do analysts recommend RGC or OGN?

Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 14.89%. Given Organon & Co.'s stronger consensus rating and higher probable upside, analysts plainly believe Organon & Co. is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Organon & Co. 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71

Which has stronger earnings & valuation, RGC or OGN?

Organon & Co. has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Organon & Co. $6.22B 0.57 $187M $0.93 14.40

Organon & Co. (OGN) Competitors

$13.40 +0.02 (+0.11%)

As of 03:41 PM Eastern

Compare

OGN vs. BBIO, SMMT, RGC, AXSM, and RDY

Should you buy Organon & Co. stock or one of its competitors? MarketBeat compares Organon & Co. with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organon & Co. include BridgeBio Pharma (BBIO), Summit Therapeutics (SMMT), Regencell Bioscience (RGC), Axsome Therapeutics (AXSM), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Organon & Co. compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, BridgeBio Pharma had 14 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for BridgeBio Pharma and 0 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.93 beat BridgeBio Pharma's score of 0.64 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Overall Sentiment
BridgeBio Pharma	Positive
Organon & Co.	Positive

BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 1.6% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.63	-$724.93M	-$3.74	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.40

BridgeBio Pharma presently has a consensus price target of $89.59, suggesting a potential upside of 36.38%. Organon & Co. has a consensus price target of $11.40, suggesting a potential downside of 14.89%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Organon & Co. has a net margin of 3.99% compared to BridgeBio Pharma's net margin of -124.42%. Organon & Co.'s return on equity of 99.95% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Organon & Co.	3.99%	99.95%	6.22%

Summary

Organon & Co. beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Summit Therapeutics?

Organon & Co. (NYSE:OGN) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market.

In the previous week, Summit Therapeutics had 8 more articles in the media than Organon & Co.. MarketBeat recorded 8 mentions for Summit Therapeutics and 0 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.93 beat Summit Therapeutics' score of 0.39 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Overall Sentiment
Organon & Co.	Positive
Summit Therapeutics	Neutral

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Organon & Co. currently has a consensus price target of $11.40, indicating a potential downside of 14.89%. Summit Therapeutics has a consensus price target of $26.05, indicating a potential upside of 73.35%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

Organon & Co. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.40
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Organon & Co. has a net margin of 3.99% compared to Summit Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Summit Therapeutics	N/A	-291.24%	-243.07%

Summary

Organon & Co. beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Organon & Co. (NYSE:OGN) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Organon & Co. has a net margin of 3.99% compared to Regencell Bioscience's net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Organon & Co.	3.99%	99.95%	6.22%

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 14.89%. Given Organon & Co.'s stronger consensus rating and higher probable upside, analysts plainly believe Organon & Co. is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

In the previous week, Regencell Bioscience had 19 more articles in the media than Organon & Co.. MarketBeat recorded 19 mentions for Regencell Bioscience and 0 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.93 beat Regencell Bioscience's score of 0.10 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Overall Sentiment
Regencell Bioscience	Neutral
Organon & Co.	Positive

Organon & Co. has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.40

Regencell Bioscience has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Summary

Organon & Co. beats Regencell Bioscience on 10 of the 12 factors compared between the two stocks.

How does Organon & Co. compare to Axsome Therapeutics?

Organon & Co. (NYSE:OGN) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Organon & Co. has a net margin of 3.99% compared to Axsome Therapeutics' net margin of -26.59%. Organon & Co.'s return on equity of 99.95% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Organon & Co. presently has a consensus price target of $11.40, suggesting a potential downside of 14.89%. Axsome Therapeutics has a consensus price target of $251.26, suggesting a potential upside of 8.53%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Organon & Co. has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.40
Axsome Therapeutics	$638.50M	18.66	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 13 more articles in the media than Organon & Co.. MarketBeat recorded 13 mentions for Axsome Therapeutics and 0 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.93 beat Axsome Therapeutics' score of 0.32 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Overall Sentiment
Organon & Co.	Positive
Axsome Therapeutics	Neutral

Summary

Organon & Co. beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Organon & Co. (NYSE:OGN) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories has higher revenue and earnings than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.40
Dr. Reddy's Laboratories	$335.93B	0.03	$484.20M	$0.58	22.51

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Organon & Co. pays out 8.6% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 10.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Organon & Co. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 14.89%. Dr. Reddy's Laboratories has a consensus target price of $16.90, suggesting a potential upside of 29.45%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Organon & Co.'s net margin of 3.99%. Organon & Co.'s return on equity of 99.95% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

In the previous week, Dr. Reddy's Laboratories had 9 more articles in the media than Organon & Co.. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 0 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.93 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Overall Sentiment
Organon & Co.	Positive
Dr. Reddy's Laboratories	Neutral

Summary

Dr. Reddy's Laboratories beats Organon & Co. on 10 of the 18 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGN vs. The Competition

Export

Metric	Organon & Co.	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$3.52B	$8.53B	$6.26B	$23.12B
Dividend Yield	0.60%	1.77%	2.69%	4.09%
P/E Ratio	14.40	22.25	22.42	30.99
Price / Sales	0.57	25.50	548.01	14.88
Price / Cash	2.31	90.05	42.31	24.78
Price / Book	4.63	5.05	9.82	4.68
Net Income	$187M	$178.24M	$3.56B	$1.07B
7 Day Performance	0.14%	-1.43%	-1.33%	-0.53%
1 Month Performance	0.76%	3.26%	3.64%	0.36%
1 Year Performance	41.97%	1.92%	27.26%	25.76%

Organon & Co. Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGN Organon & Co.	2.6951 of 5 stars	$13.40 +0.1%	$11.40 -14.9%	+45.2%	$3.52B	$6.22B	14.40	10,000
BBIO BridgeBio Pharma	3.4676 of 5 stars	$69.12 flat	$88.90 +28.6%	+80.1%	$13.54B	$502.08M	N/A	400	Analyst Forecast
SMMT Summit Therapeutics	2.148 of 5 stars	$16.62 flat	$26.05 +56.8%	-16.2%	$12.90B	N/A	N/A	110	Analyst Forecast
RGC Regencell Bioscience	0.1342 of 5 stars	$25.80 flat	N/A	N/A	$12.76B	N/A	N/A	10	Gap Up
AXSM Axsome Therapeutics	2.6506 of 5 stars	$235.97 flat	$251.26 +6.5%	+106.4%	$12.14B	$638.50M	N/A	380	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:OGN) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organon & Co. (OGN) Competitors

OGN vs. BBIO, SMMT, RGC, AXSM, and RDY

How does Organon & Co. compare to BridgeBio Pharma?

Summary

How does Organon & Co. compare to Summit Therapeutics?

Summary

How does Organon & Co. compare to Regencell Bioscience?

Summary

How does Organon & Co. compare to Axsome Therapeutics?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organon & Co. (OGN) Competitors

OGN vs. BBIO, SMMT, RGC, AXSM, and RDY

How does Organon & Co. compare to BridgeBio Pharma?

Does the media refer more to BBIO or OGN?

Which has more risk & volatility, BBIO or OGN?

Do institutionals and insiders have more ownership in BBIO or OGN?

Which has higher valuation & earnings, BBIO or OGN?

Do analysts prefer BBIO or OGN?

Is BBIO or OGN more profitable?

Summary

How does Organon & Co. compare to Summit Therapeutics?

Which has more risk & volatility, OGN or SMMT?

Does the media prefer OGN or SMMT?

Do institutionals & insiders believe in OGN or SMMT?

Do analysts rate OGN or SMMT?

Which has stronger valuation and earnings, OGN or SMMT?

Is OGN or SMMT more profitable?

Summary

How does Organon & Co. compare to Regencell Bioscience?

Is RGC or OGN more profitable?

Do institutionals and insiders believe in RGC or OGN?

Do analysts recommend RGC or OGN?

Does the media refer more to RGC or OGN?

Which has stronger earnings & valuation, RGC or OGN?

Which has more risk and volatility, RGC or OGN?

Summary

How does Organon & Co. compare to Axsome Therapeutics?

Do insiders and institutionals hold more shares of OGN or AXSM?

Is OGN or AXSM more profitable?

Which has more risk & volatility, OGN or AXSM?

Do analysts recommend OGN or AXSM?

Which has preferable valuation and earnings, OGN or AXSM?

Does the media prefer OGN or AXSM?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Do insiders & institutionals have more ownership in OGN or RDY?

Which has better valuation & earnings, OGN or RDY?

Is OGN or RDY a better dividend stock?

Do analysts prefer OGN or RDY?

Is OGN or RDY more profitable?

Which has more volatility & risk, OGN or RDY?

Does the media prefer OGN or RDY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools